英矽智能与康哲药业达成数千万港元的中枢神经系统及自身免疫疾病领域的多个药物研发项目合作

Core Viewpoint - Insilico Medicine (03696) has announced a strategic collaboration with Kanghong Pharmaceutical for drug development, focusing on AI-enabled innovative drug research in central nervous system and autoimmune disease areas [1] Group 1: Collaboration Details - The collaboration will leverage Insilico's validated AI platform and innovative drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - The agreement stipulates that both parties will jointly advance at least two research projects [1] Group 2: Financial Aspects - Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]